Objectives: To describe the methodology to estimate the total cost of administration of a single unit of red blood cells (RBC) in adults with beta thalassaemia major in an Australian specialist haemoglobinopathy centre.
Thalassaemia major is a genetic disorder characterised by abnormal or reduced production of alpha or beta globin chains, leading to ineffective erythropoiesis and chronic haemolytic anaemia (Taher et al., 2018) . Thalassaemia represents a major public health concern with significant disease burden (World Health Organization, 2017) . Transfusion-dependent thalassaemia (TDT), typically beta thalassaemia major, severe haemoglobin H disease and severe haemoglobin E/beta-thalassaemia, requires lifelong red blood cell (RBC) transfusion for survival, optimal growth and development and prevention of complications from extramedullary haematopoiesis (Liu & Grossman, 2015) . However, frequent RBC transfusion is also associated with hazards, including alloimmunisation and iron overload.
Medical management of TDTs aims to ameliorate anaemia, suppress ineffective erythropoiesis and use chelation to control iron overload and its end-organ consequences (Cappellini et al., 2014) . Allogeneic stem cell transplantation is currently the only definitive cure for TDTs (Srivastava & Shaji, 2017) . However, recent advances in understanding the mechanisms leading to ineffective erythropoiesis, iron overload and transition of fetal to adult haemoglobin, have identified promising therapeutic targets for patients with thalassaemia (Makis et al., 2016) . Many new agents are currently in trials or being introduced into clinical practice (Taher et al., 2018) . As new treatments are developed, they must be compared with current therapy to evaluate efficacy and costs.
First published online 10 April 2018
The costs of providing RBC transfusion support are not well defined. These costs are not limited to the collection and manufacturing of RBC components. Previous research has reported that transfusion-related clinical and laboratory costs are underestimated and geographically variable, with one study indicating that these may be up to 4·8 times higher than the RBC acquisition costs (Shander et al., 2010) . No previous studies have described costs for providing chronic transfusion therapy, which may be higher due to the complexity of transfusion care for these patients.
Transfusion is also a complex process. Human factors are acknowledged to contribute to many transfusion complications (Bolton-Maggs et al., 2015) . Describing in detail the many individual steps, handover points and complexities may help better identify and understand the complexity, in order to address the potential 'weak links in the chain' in clinical and laboratory practice and improve transfusion safety.
Here we describe the study design for the TRUSTT (True Cost of Transfusion in Thalassaemia) project -a bottom-up, time-driven, activity-based costing (TDABC) study to accurately determine the cost of RBC transfusion for TDTs in Australia.
MATERIALS AND METHODS

Ethics, consent and permissions
This study is approved by Monash University and the Monash Medical Centre Human Research Ethics Committees. Data are collected on processes and no individual, patient-identifiable data will be obtained. The units of observation in this study are the processes involved in the preparation and administration of a RBC unit, and not the patient. Therefore, a waived consent model is used. The study meets conditions for waived consent as outlined in Australia's National Statement on Ethical Conduct in Human Research (National Health and Medical Research Council, 2007) .
Project aim
The aim of the study was to perform a TDABC study to accurately determine the total cost of administration of a single unit of RBC in an adult patient with beta thalassaemia major.
Study design
To understand all costs of the transfusion process on a detailed level, a TDABC study design was selected. TDABC is a well-described costing model, which has been used in a variety of industries, including healthcare. It allows for an accurate account of expenditure of providing care that is calculated by summing costs over the full episode of care for a selected patient condition. The total cost is dependent on the real use of resources involved throughout all steps of the episode of care and includes the proportion of time assigned by each resource as well as the cost of each resource per unit of time (Laviana et al., 2016) . TDABC allows for all costs, such as staff, equipment, facility and support to be precisely assigned by combining process-mapping of all activities involved in the episode of care with activity-based costing (ABC) methods (Kaplan et al., 2014) .
The study is designed in accordance with recommendations for performing a TDABC by Keel et al. (2017) to accurately undertake cost analysis for each process and overall transfusion activity. Fig. 1 outlines the seven steps of TDABC described by Keel et al. (2017) and the TRUSTT methodology interpretation to correlate with these steps.
Setting
Monash Medical Centre (MMC) is a 640-bed university teaching hospital in metropolitan Melbourne, Victoria (state population 6·2 million), Australia. MMC provides a comprehensive range of medical and surgical services and is the designated statewide provider of specialist thalassaemia services.
The medical therapy unit (MTU) at MMC provides a whole-of-life service for patients with inherited RBC disorders. Most transfusions occur in the MTU outpatient facility. All immunohaematology testing and issue of RBCs for transfusion in the MTU is performed by a comprehensive on-site laboratory service, Monash Pathology.
Monash Pathology's transfusion service is a predominantly automated laboratory and uses Ortho Clinical Diagnostics (OCD) BioVue© (Raritan, NJ, USA), glass bead column agglutination technology (CAT). AutoVue Innova (OCD) analysers perform a large proportion of routine patient testing, including blood groups, antibody screens, antibody identifications, direct antiglobulin tests, indirect antiglobulin test (IAT) crossmatching and IAT phenotyping. Manual tube procedures are also used for further antibody investigations, resolving group discrepancies and other tests where CAT is not appropriate.
Patients
The study included adult patients with beta thalassaemia major receiving RBC transfusions at MMC.
Developing process maps
Costs to be included are those considered to be directly related to the provision of the RBC or complications from RBC therapy for adult beta thalassaemia patients. Given the specific aim of the study, costs to be excluded from analysis are those not considered directly related to RBC transfusion therapy, broader societal costs and costs specific to other patient populations. Table 1 lists in-scope and out-of-scope study costs.
The RBC transfusion episode is divided into four phases: 
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Fig. 1. (a)
The seven steps of time-driven, activity-based costing (TDABC) for health care organisations as outlined by Keel et al. (2017) 
and (b) True
Cost of Transfusion in Thalassaemia (TRUSTT) methodology interpretation to correlate with these steps.
3 Patient admission for RBC administration and 4 Associated treatments and processes directly related to the transfusion.
For each phase, a senior staff member provided a background/overview of the activities involved. Each step in an activity was identified along with all resources, equipment, consumables and staff involved. The activities were compiled into process maps, referenced against standard operating procedures for each department and verified. A master process map was developed ( Fig. 2 ) and detailed individual flowcharts for each process were created, which outlined the component activities of each process. Each process has an associated process map which contains a detailed flowchart, including probabilities of alternate pathways that could occur due to variations in testing results, patient condition and other processes. Combined, these individual process maps provide a step-by-step outline of the entire transfusion pathway. Table 2 outlines the individual processes. Each individual process map is provided in Appendix S1 (Laboratory), Appendix S2 (Clinical) and Appendix S3 (Pharmacy), Supporting Information.
Observations and data collection
With the maps now developed, observations and detailed data collection will be performed for a range of activities, including phlebotomy, transfusion-related laboratory testing, pharmacy dispensing and RBC administration.
For the purpose of our study, process sampling commences at patient presentation for phlebotomy for pre-transfusion laboratory testing (≤7 days prior to transfusion) at the hospital, or when a pre-transfusion specimen is collected from an external Out-of-scope costs 1. Costs specific to other transfusion-dependent conditions other than beta thalassaemia 2. Treatments for other comorbidities associated with beta thalassaemia that are not RBC transfusion-related 3. Treatments for transfusion-transmitted infection (TTI). The incidence of a viral TTI occurring in Australia in 2017 is extremely rare (<1 in 2 million) 4. Societal costs for individual donors or patients 5. Clinical and laboratory investigations to establish the underlying diagnosis, or cause of the anaemia (e.g., costs for haemolysis screen) 6. Donation-related or transport costs associated with the delivery of RBCs to hospital by the Australian Red Cross Blood Service site and received at Monash Pathology. The sampling episode concludes with the patient's post-transfusion discharge from the MTU, or at completion of the final unit transfused for that episode, in the ward setting, or at the completion of a transfusion reaction investigation. Each department at the hospital involved in the laboratory testing, RBC administration or pharmacy dispensing of medication used to treat the long-term consequences of RBC transfusion (e.g. iron overload) is visited to directly observe the procedures and conduct interviews with the relevant staff. Similar to a TDABC study performed by Erhun et al. (2015) , during the site visits, the following data are recorded:
1 All activities involved in the RBC transfusion admission episode 2 Persons performing each activity 3 Resources utilised (e.g., consumables and equipment) 4 Length of time to perform each activity and 5 Probability of occurrence of each activity.
While performing direct and contextual observations, patients and staff are directly informed by senior staff members and the study team about what is being observed and the rationale behind the study.
All major activities have multiple timings performed and involve timing multiple staff members performing the same activities on different days in order to obtain an average of timings allowing for staff variation. Expert opinion estimates will be obtained for all flowchart decision node probabilities and some low occurrence events among this patient cohort. Recall bias is minimised by recording observations as they occur.
All data collected (timings, process maps, probabilities, unit costs) are checked and validated by staff/experts from the relevant departments.
Data analysis
Costs will be broken down into fixed costs, variable costs and RBC procurement costs.
Fixed costs. Fixed costs associated with the transfusion of TDTs will be broken down into equipment and maintenance costs; MTU expenses and overheads; and fixed staff and governance. MMC or the manufacturer will determine costs of equipment procurement, maintenance, salvage value and lifespan. The total monthly cost for having a particular piece of equipment will then be evaluated by ascertaining what percentage of the monthly cost is attributable to the transfusion of TDTs. This will then be translated into cost per RBC transfused. MTU expenses and overheads (including utilities) will be provided by MMC. These monthly expenses will then be converted into a TDT monthly cost and cost per RBC. Fixed staff and governance costs will be broken down into transfusion governance-related meetings; external quality assurance programmes; and fixed administration and nursing staff costs. For each component, the relevant staff, consumables and time dedicated to the governance, administration and management tasks associated with transfusion of TDTs will be determined. This will be informed by using expert opinion from staff at MMC. The total monthly cost associated with these tasks will then be evaluated and converted into cost per RBC.
Variable costs. Individual process costs will be calculated based on direct observations of the staff performing tasks within the processes, as well as the time taken to perform these tasks and the associated consumables used. Supplementary to direct observations, expert opinion and statistics will be used to inform the probabilities of a given task occurring within a process. The consumable costs will be provided by the MMC, and staff hourly Pharmacy (see Appendix S3) 1. Pharmacy dispensing of iron chelation therapy wages will be determined from the relevant awards for all staff. The wages will then be inflated to capture the costs for all nursing, laboratory, pharmacy, administration and technical staff. The individual process cost will then be evaluated as the sum of all possible tasks that could occur within that process multiplied by the probability of that task occurring. See Appendix S4 for a sample cost calculation for an individual process. These costs will be evaluated as cost per TDT admission, TDT cost per month and cost per RBC. The total overall process costs will then be evaluated by determining how many times a given process occurs in a month.
RBC procurement cost. The average cost of the RBCs will be evaluated based on the unit RBC price. The Australian government pays the Australian Red Cross Blood Service (ARCBS) to make and supply RBCs to hospitals, with the price of all blood and blood products negotiated on an annual basis between the ARCBS and the National Blood Authority. As at 1 July 2016 the agreed price for washed leucodepleted and leucodepleted RBCs are $405·94 and $401·94, respectively (Australian Red Cross Blood Service, 2016). It must be noted that this is a price charged, not a cost, and is not necessarily reflective of the actual cost for producing the units. The average unit cost per RBC will then evaluated based on the number of washed leucodepleted and leucodepleted RBCs used in March 2017.
Total cost. The total cost will then be finalised by summing the fixed costs, variable costs and RBC procurement costs.
Sensitivity analyses will be performed on the probabilities associated with performing different tasks within processes; the staff performing different tasks; the time taken to perform different tasks; the number of patient admissions; and the number of RBCs transfused in an admission.
RESULTS
Thirty-one process maps (23 laboratory, 7 clinical and 1 pharmacy) describing over 600 individual activities have been developed (see Fig. 2 and Table 2 ). Each requires multiple timings to account for variation in practice (relating to patient or staff factors, or circumstances). Infrequent events unable to be timed will be estimated by experts at interview. Individual process maps are provided in Appendices (see Appendix S1 for laboratory process maps, Appendix S2 for clinical process maps and Appendix S3 for the pharmacy process map).
Transfusion laboratory processes are the most complex, due to the various testing protocols required for this cohort of patients, and the number of steps requiring decisions based on current and historical test results. While a large proportion of immunohaematology testing is performed on automated analysers, process maps for manual methods ensure all possible events are captured.
DISCUSSION
To our knowledge, this is the first paper to describe a detailed methodology to determine the true cost of RBC transfusion for a chronically transfused patient population of TDTs using TDABC.
RBC transfusion is a complex, multidisciplinary process consisting of many separate stages, including clerical, administrative, laboratory, nursing and medical activities. All of these processes, as well as consumables, infrastructure and equipment, need to be included to determine the total cost of transfusion therapy. Varying circumstances due to patient, environmental and other factors, can influence staffing requirements, equipment and consumables -and hence time taken, and resources required for each process and individual activity -and therefore must be considered for a comprehensive understanding of the overall cost.
Few published studies have reported on the cost of blood transfusion or provided a detailed methodology. Shander et al. (2010) studied the costs of blood transfusions in surgical patients at four hospitals in the United States and Europe using an ABC method from a health system perspective. They concluded the ABC methodology is the most detailed and rigorous. However, their study was limited to surgical patients and included patients who were tested for, but did not receive, a transfusion. They concluded that patients who do not receive transfusions also contribute considerably to hospital expenses due to resource consumption with laboratory testing and preparation. The methodology described by Shander et al. (2010) was therefore not directly applicable to our study as we are investigating the costs of a very different cohort of transfusion-dependent patients, with every sample tested resulting in a RBC transfusion. We are also including in-depth process mapping of all transfusion laboratory processes, which have not previously been described. Cantor et al. (1998) studied the cost of blood transfusions in the cancer care setting using a process-flow analysis method. This structured interview-based study determined the sequence of events of the transfusion process but did not include any in-depth timings, observations or documentation of resources.
The strength of our study design is the application of a bottom-up TDABC, which can achieve cost granularity and improve understanding of actual costs by documenting all activities and resources involved in a RBC transfusion. The TDABC model uses time equations to estimate the time spent on each activity and to capture operational processes with detail in a straightforward and efficient manner (Akhavan et al., 2016) . In addition, we have mapped 31 individual processes, of which 23 demonstrate the complex laboratory testing required, providing suitable RBCs for TDTs and taking into account both automated and manual methods in use. In the next part of the study, we will perform a minimum of three timings of each individual activity that contributes to a process map, to document and understand variation, improve accuracy and validate our results.
Limitations of our study are the inclusion of only adult thalassaemia patients from a single-centre outpatient setting, which may limit the generalisability of our findings. However, our detailed process maps could be readily adapted to other studies at other sites and in other clinical settings, such as myelodysplastic syndromes and sickle cell anaemia. They will also have the potential to be adapted to perform cost analysis of other components such as platelets, fresh frozen plasma and cryoprecipitate; fractionated products such as immunoglobulins; or to evaluate the cost of fibrinogen concentrate when compared to cryoprecipitate.
In addition, provision of sensitivity analysis is a key part of the method, to describe different processes that may have greater effect on overall cost and inform what differences between hospital processes or procedures may alter the cost.
Describing the numbers of steps and processes that must be integrated on every occasion to achieve a safe and timely transfusion also highlights the complexity of current transfusion practice. This complexity carries inherent risks, which can be susceptible to, or compounded by, human factors. Availability of detailed process maps may permit greater clarity of the potential 'weak links in the chain' and identify areas of future focus to improve safety.
CONCLUSIONS
This paper describes in detail, for the first time, a bottom-up TDABC method to understand the cost of transfusing a unit of RBC, in this case for Australian patients with transfusion-dependent beta thalassaemia. It provides process maps that may be adapted for costing studies of other blood components and in other clinical settings, and may also be useful for haemovigilance purposes.
